Natco Pharma Limited has informed the Exchange regarding a press release dated November 12, 2025, titled "Adcock Ingram Holdings Limited completes delisting from Johannesburg Stock Exchange and NATCO Pharma Limited acquires 35.75% stake".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has informed the stock exchange about a press release dated November 12, 2025, announcing that it has acquired a 35.75% stake in Adcock Ingram Holdings Limited. Adcock Ingram has completed its delisting from the Johannesburg Stock Exchange (JSE), paving the way for this stake acquisition by Natco. This marks a significant international expansion move for the Indian pharmaceutical company into the South African market. The transaction positions Natco as a major shareholder in one of South Africa's leading pharmaceutical companies.
This acquisition strengthens Natco Pharma's international footprint and provides direct access to the South African pharmaceutical market. Shareholders may view this positively as it represents strategic overseas expansion, though integration risks and capital deployment concerns should be monitored. The stock may see positive momentum given the scale of the acquisition.